
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 27 years ago
Participating Facultyover 27 years ago
Introductionover 27 years ago
An Overview of Integrated Managed Careover 27 years ago
Selected Abstractsover 27 years ago
Bibliography





